| Execution period | Up to 28 February, 2031 |
|---|
NSE filing, NSE: EPWINDIA. Summary written from the filing by ALFA Finder's alert engine.
EPW India Ltd: key numbers
- Share price
- ₹240.00
- Market cap
- ₹275.5 Cr
- Revenue (annual)
- ₹101.8 Cr
- Net profit (annual)
- ₹10.07 Cr
- P/E (TTM)
- 27.4×Sector 45.8×
- Promoter holding
- 71.43%
- FII holding
- 3.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from EPW India Ltd
All →EPW India Other Announcement
EPW India Limited filed a non-applicability certificate for the Q2 FY27 Corporate Governance Report under Reg 27(2) LODR. As an NSE Emerge (SME) listed entity, the corporate governance reporting requirement does not apply.
EPW India Management Change
EPW India Limited informed NSE of Ms Deepika Gupta's resignation as Company Secretary and Compliance Officer. The KMP departure is effective 15 October 2026 for personal reasons.
EPW India Other Announcement
EPW India Limited submitted a certificate confirming non-applicability of Regulation 74(5) for the quarter ended September 30, 2026, as all shares are in dematerialized form.
EPW India Acquisition Worth ₹1.17 Cr
EPW India Limited acquired 100% of UAE-based Exclusive PC World Computers & Requisites Trading L.L.C for AED 4.48 Lakhs (approx. ₹1.17 Crore) to expand international operations.
- Value
- ₹1.17 Cr
EPW India Debt & Borrowing: ₹35 Cr
EPW India Limited approved a cash credit facility and working capital term loan of ₹35.00 Crore from ICICI Bank Limited.
- Value
- ₹35.00 Cr
EPW India Annual General Meeting
EPW India Limited held its 5th Annual General Meeting on September 08, 2026. The meeting covered the adoption of financial statements and the re-appointment of a director.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.